Topical Application of TAT-Superoxide Dismutase in Acupoints LI 20 on Allergic Rhinitis

Table 1

Characteristics of subjects in TTA, placebo, and TTN groups, mean (SEM).

Parameter/treatment	TTA	Placebo	TTN	value	value
Baseline assessment
Number	21	17	18	NA	NA
Age (y), mean (SEM)	30.0 (10.3)	30.6 (12.4)	30.2 (11.2)	0.43	0.95
Sex (M/F)	8/13	7/10	7/11	NA	NA
Skin test (number of positive patients)
Dust mite	18	15	15	NA	NA
Cat	0	0	0	NA	NA
Dog	0	0	0	NA	NA
Mold	3	2	3	NA	NA
Dust mite wheal (mm), mean (SEM)	9.0 (1.2)	9.4 (0.6)	9.2 (0.7)	0.18	0.54
Course of disease (y), mean (SEM)	6.5 (4.8)	7.4 (5.1)	7.5 (3.2)	0.58	0.46
Symptom score, mean (SEM)
Stuffiness	1.8 (0.6)	1.9 (0.6)	1.8 (0.6)	0.71	0.99
Sneezing	1.4 (0.6)	1.4 (0.6)	1.5 (0.8)	0.89	0.66
Rhinorrhea	1.8 (0.8)	1.9 (0.8)	1.9 (0.6)	0.78	0.67
Itching	1.9 (0.8)	1.9 (0.9)	1.9 (0.8)	0.93	0.99
Total	6.9 (1.8)	7.1 (1.8)	7.1 (1.7)	0.87	0.72
Day 8
Symptom score, mean (SEM)
Stuffiness	1.3 (0.6)	1.5 (0.5)	1.6 (0.6)	0.44	0.13
Sneezing	1.2 (0.6)	1.2 (0.5)	1.4 (0.6)	0.93	0.31
Rhinorrhea	1.3 (0.6)	1.8 (1.0)	1.9 (0.6)	0.09	<0.01
Itching	1.3 (0.6)	1.9 (0.6)	1.9 (0.6)	<0.001	<0.001
Total	5.1 (1.3)	6.4 (1.2)	6.8 (1.1)	<0.01	<0.001
Day 15
Symptom score, mean (SEM)
Stuffiness	0.8 (0.6)	1.7 (0.6)	1.6 (0.7)	<0.001	<0.001
Sneezing	0.4 (0.6)	1.4 (0.8)	1.4 (0.6)	<0.001	<0.001
Rhinorrhea	1.0 (0.7)	1.5 (0.6)	1.9 (0.6)	0.01	<0.001
Itching	0.8 (0.6)	2.1 (0.7)	2.0 (0.5)	<0.001	<0.001
Total	3.0 (1.7)	6.7 (1.2)	6.9 (1.1)	<0.001	<0.001
Therapeutic response, number (percentage)
Deterioration	1 (4.8%)	2 (11.7%)	3 (16.7%)	NA	NA
None	3 (14.3%)	14 (82.4%)	15 (83.3%)	NA	NA
Moderate	10 (47.6%)	1 (5.9%)	0 (0%)	NA	NA
Marked	7 (33.3%)	0 (0%)	0 (0%)	NA	NA

NA, not applicable.
Two-sample -test comparing treatment means of TTA versus placebo.
Two-sample -test comparing treatment means of TTA versus TTN.